Universe Pharmaceuticals
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
109% more capital invested
Capital invested by funds: $165K [Q3] → $344K (+$179K) [Q4]
23.99% more ownership
Funds ownership: 2.86% [Q3] → 26.85% (+23.99%) [Q4]
56% less funds holding
Funds holding: 9 [Q3] → 4 (-5) [Q4]
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for UPC.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Universe Pharmaceuticals INC Announces Share Consolidation
Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the “Share Consolidation”). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders.
Neutral
GlobeNewsWire
1 month ago
Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report
Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the “Form 20-F”) and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1).
Neutral
GlobeNewsWire
1 month ago
Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request
Ji'an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company's listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Rule. However, pursuant to the Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split on November 18, 2024, or within the prior one-year period.
Neutral
GlobeNewsWire
3 months ago
Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)
New York, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) of its client Universe Pharmaceuticals INC (NASDAQ: UPC) (the “Company”), a pharmaceutical producer and distributor in China.
Neutral
GlobeNewsWire
4 months ago
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ji'an, Jiangxi, China, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on October 25, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.
Neutral
GlobeNewsWire
6 months ago
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024
JI'AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2024 ended March 31, 2024.
Negative
InvestorPlace
1 year ago
Why Is Universe Pharmaceuticals (UPC) Stock Down 29% Today?
Universe Pharmaceuticals (NASDAQ: UPC ) stock is falling on Tuesday after the company's shares experienced a rally during the prior day of trading. Shares of UPC closed out Friday up 43.9% without any clear news from the traditional Chinese medicine company.
Neutral
PRNewsWire
1 year ago
Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results
JI'AN, China, Jan. 30, 2024 /PRNewswire/ -- Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its financial results for the fiscal year ended September 30, 2023. Mr. Gang Lai, Chairman and Chief Executive Officer of Universe Pharmaceuticals, commented, "Despite market fluctuations and the economic slowdown impacting our business in fiscal year 2023, we continued our efforts to deliver high quality products to our loyal customers.
Charts implemented using Lightweight Charts™